Details:
AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.
Lead Product(s): AZP-3813
Therapeutic Area: Endocrinology Product Name: AZP-3813
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: PeptiDream
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
AZP-3601, a long-acting parathyroid hormone (PTH) analog, normalizes blood calcium in thyroparathyroidectomized (TPTX) rats without causing deleterious changes in bone.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
AZP-3601, investigational therapeutic peptide designed to target specific conformation of PTH receptor safely produce sustained and stable levels of calcium in blood and manage symptoms of hypoparathyroidism, with goal of consequently preventing chronic kidney disease.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
This acquisition strengthens the protection and the potential of the First in Class drug candidate of T.H.A.C which incorporates the active ingredient ALF-5755 for the treatment of Type 2 Diabetes Mellitus and severe complications.
Lead Product(s): ALF-5755
Therapeutic Area: Endocrinology Product Name: ALF-5755
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: T.H.A.C.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 27, 2021
Details:
Amolyt will use the proceeds to advance its pipeline for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Sectoral Asset Management
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 16, 2021
Details:
Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Lead Product(s): Insulin Lispro,Pramlintide
Therapeutic Area: Endocrinology Product Name: BC LisPram
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
Data from all cohorts from its Phase 1 Single Ascending Dose clinical trial evaluating AZP-3601, a parathyroid hormone (PTH) analog specifically designed for the treatment of hypoparathyroidism will be presented.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
AZP-3601 is a therapeutic peptide designed to target a specific configuration of the parathyroid hormone (PTH) receptor in order to safely produce sustained levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: AZP-3601
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021